Prost Biotech | NAD+, Semaglutide, Tirzepatide & Retatrutide — Research Peptides
glunovabio.com
LaunchIndex first observed Prost Biotech | NAD+, Semaglutide, Tirzepatide & Retatrutide — Research Peptides (glunovabio.com) live on 20 August 2026. View its launch screenshot, category, technologies, and verification evidence.
A launch record built from evidence.
Prost Biotech | NAD+, Semaglutide, Tirzepatide & Retatrutide — Research Peptides (glunovabio.com) was first observed live on 20 August 2026.
Educational resources about NAD+ therapy, GLP-1 medications (semaglutide, tirzepatide, retatrutide), FDA status in 2026, and metabolic health optimization. Content emphasizes education and guidance from evidence-based sources.
Its profile is classified as Ecommerce store within Education / Learning and training. Verification detected Next.js and Google Analytics.
What the launch signal contained.
- First observed live
- Previous state
- No prior non-live observation
- Last verified
- Canonical host
- www.glunovabio.com
- Category
- Education / Learning and training
- Website type
- Ecommerce store
- Observed title
- Prost Biotech | NAD+, Semaglutide, Tirzepatide & Retatrutide — Research Peptides
- Observed description
- Evidence-based educational resources about NAD+ therapy, GLP-1 medications (Semaglutide, Tirzepatide, Retatrutide), retatrutide FDA approval status 2026, and metabolic health optimization.
- Detected technologies
- Next.jsGoogle Analytics
- Screenshot captured
- Evidence source
- Browser observation · Local
- Evidence confidence
- 93%
- HTTP status
- 200
Is this your website?
Claim this profile to add verified owner information.
What do you make of this launch?
Vote on the site and leave a short note for other people exploring the new web.
Report an issueFlag spam, illegal or harmful content, or inaccurate information.
Reports are private and reviewed by the moderation team. No sign-in is required, so this report will be anonymous.
Join the discussion
Sign in with Google to vote or comment.
Sign in to participateComments
0 commentsBe the first to leave a useful observation.